Skip to main content
. 2024 Sep 11;41(11):4125–4139. doi: 10.1007/s12325-024-02975-x

Fig. 1.

Fig. 1

ORR and DOR according to tumor type and HER2 IHC status by the local or central test result used for study enrollment by a investigator assessment and b ICR in patients with IHC 3+ and IHC 2+ tumors. BTC biliary tract cancer, CI confidence interval, DOR duration of response, HER2 human epidermal growth factor receptor 2, ICR independent central review, IHC immunohistochemistry, NE not estimable, ORR objective response rate